Thus, with the reduction of CTLA‐4 and TIM‐3 expression, the function of Treg was clearly impaired, meanwhile the significant drop of IL‐10 in serum also gave strong support for it, suggesting lenvatinib might affect immune to some extent to improve the immune status of patients with HCC. This evidence concerns the gene HAVCR2 and hepatocellular carcinoma.